Gilead Sciences, Inc.
GILD
$125.00
$1.090.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.78% | 3.81% | 4.68% | 6.04% | 3.32% |
| Total Other Revenue | 0.00% | 0.00% | -- | -- | -- |
| Total Revenue | 2.78% | 3.81% | 4.69% | 6.04% | 3.32% |
| Cost of Revenue | -1.43% | -1.21% | 1.12% | 3.85% | 8.22% |
| Gross Profit | 3.99% | 5.27% | 5.72% | 6.67% | 2.00% |
| SG&A Expenses | 1.26% | 4.00% | -4.00% | -1.01% | -12.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.36% | 1.17% | -1.50% | 1.27% | -3.00% |
| Operating Income | 6.81% | 8.37% | 16.56% | 15.23% | 15.85% |
| Income Before Tax | 5,485.31% | 367.90% | 534.88% | -89.93% | -97.55% |
| Income Tax Expenses | 2,719.05% | 75.89% | 39.38% | -83.09% | -95.53% |
| Earnings from Continuing Operations | 7,014.04% | 510.94% | 1,202.40% | -91.45% | -98.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -74.47% |
| Net Income | 6,336.51% | 499.34% | 1,132.44% | -91.53% | -97.86% |
| EBIT | 6.81% | 8.37% | 16.56% | 15.23% | 15.85% |
| EBITDA | 5.44% | 6.70% | 13.07% | 12.42% | 14.38% |
| EPS Basic | 6,407.19% | 501.26% | 1,144.01% | -91.54% | -97.87% |
| Normalized Basic EPS | 7.28% | 7.90% | 15.63% | 13.91% | 15.49% |
| EPS Diluted | 8,473.77% | 522.15% | 1,273.20% | -92.09% | -98.39% |
| Normalized Diluted EPS | 6.75% | 7.51% | 15.44% | 14.27% | 16.02% |
| Average Basic Shares Outstanding | -0.14% | -0.08% | -0.08% | -0.08% | -0.16% |
| Average Diluted Shares Outstanding | 0.38% | 0.32% | 0.10% | -0.42% | -0.63% |
| Dividend Per Share | 2.61% | 2.63% | 2.65% | 2.67% | 2.68% |
| Payout Ratio | -0.98% | -0.83% | -0.92% | 11.14% | 46.95% |